Evaluasi Klinis dan Efek Samping Terapi Obat Antivirus Pada Pasien Covid-19 Di RSPAD Gatot Soebroto

https://doi.org/10.33860/jik.v16i2.1333

Authors

  • Jeanette Mangiwa Program Magister Ilmu Kefarmasian, Universitas Pancasila, DKI Jakarta, Indonesia
  • Ros Sumarny Program Magister Ilmu Kefarmasian, Universitas Pancasila, DKI Jakarta, Indonesia
  • Dian Ratih Laksmitawati Program Magister Ilmu Kefarmasian, Universitas Pancasila, DKI Jakarta, Indonesia
  • Renni Septini Instalasi Farmasi RSPAD Gatot Soebroto, DKI Jakarta, Indonesia

Keywords:

Covid-19, Evaluasi, Klinis, Antivirus, Efek Samping, Lama rawat

Abstract

Tujuan penelitian ini adalah untuk menganalisa hubungan jenis obat antivirus Covid-19 dengan outcome klinis dan lama rawat berdasarkan derajat keparahan Covid-19 di ruang rawat inap Paviliun Soehardo Kertohusodo RSPAD Gatot Soebroto Jakarta. Penelitian ini merupakan penelitian observasional analitik dan pengambilan data secara retrospektif melalui rekam medis periode bulan September - November tahun 2020. Sampel adalah pasien Covid-19 derajat sedang dan berat. Data demografi dan klinis pasien serta profil pengobatan dianalisis secara deskriptif berdasarkan derajat keparahan Covid-19. Analisis data yaitu uji Spearman’s rho. Hasil menunjukkan terdapat 79 pasien Covid-19 yang memenuhi kriteria inklusi dengan derajat sedang 62,03% dan derajat berat 37,97%. Penggunaan antivirus pada derajat sedang yaitu oseltamivir sebanyak 28 pasien (57,14%), favipiravir 13 pasien (26,53%) sedangkan penggunaan antivirus pada derajat berat adalah oseltamivir & favipiravir. Hubungan lama status positif RT-PCR dan lama rawat terhadap derajat keparahan Covid-19 diperoleh p <0,05. Hubungan profil penggunaan obat antivirus dengan derajat keparahan Covid-19 diperoleh p=0,00. Hubungan jenis regimen obat antivirus dengan nilai skala rasio parameter klinik d-dimer pre p=0,01 dan post p=0,03 dan parameter klinik SGPT (pre) p=0,04 da (post) p=0,00 pada derajat berat. Kesimpulan yaitu terdapat hubungan yang signifikan profil penggunaan regimen obat antivirus dengan derajat keparahan Covid-19 dan terdapat hubungan yang signifikan pada penggunaan obat penunjang yaitu antikoagulan, antihistamin, obat gangguan saluran cerna dan obat hepaprotektor dengan derajat keparahan Covid-19

References

World Health Organization (WHO). Naming the coronavirus disease (COVID-19) and the virus that causes it.

World Health Organization (WHO). Transmission of SARS-CoV2 implications for infection prevention precautions. 2020.

Centers for Disease Control and Prevention. Coronavirus Disease 2019: Transmission. 2020.

Badan Pengawas Obat dan Makanan Republik Indonesia. Langkah Strategis Badan POM dalam Penanganan Obat COVID-19. Jakarta; 2020. 1–14 p.

RSPAD Gatot Soebroto. Administrasi Pasien (Min-pasien). 2020;Jakarta.

Chairani I. Dampak Pandemi COVID-19 Dalam Perspektif Gender Di Indonesia. Jurnal Kependudukan Indonesia. 2020 Jul;39-42 p.

Pemerintah Provinsi DKI Jakarta 2021 [Internet]. 2021 [cited 2021 Feb 5]. Available from: https://corona.jakarta.go.id/id/data-pemantauan

Mukherjee S, Pahan K. Is COVID-19 Gender-sensitive? Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2021 Mar;16(1):38–47.

Haryati H, Isa M, Assagaf A, Nurrasyidah I, Kusumawardhani E. Clinical Characteristics of Hospitalized Individuals Dying with COVID-19 in Ulin Regional Hospital Banjarmasin. Jurnal Respirasi. 2021;7(1):1.

Abbas A et al. Cellular and molecular immunology, 9th. Saunders Elsevier. 2018;

Cortis D. On Determining the Age Distribution of COVID-19 Pandemic. Frontiers in public health. 2020;8:202.

Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature medicine. 2020 Aug;26(8):1205–11.

Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of infection and public health. 2020 Dec;13(12):1833–9.

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020 May;94:91–5.

Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2014 Apr;22(2):83–94.

Yu B, Li X, Chen J, Ouyang M, Zhang H, Zhao X, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. Journal of thrombosis and thrombolysis. 2020 Oct;50(3):548–57.

Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology : journal of immunopathology, molecular and cellular biology. 2021;88(1):15–27.

Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, et al. Elevated D-Dimer Levels Are Associated With Increased Risk of Mortality in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Cardiology in review. 2020;28(6):295–302.

Badan Pengawas Obat dan Makanan Republik Indonesia. Informatorium Obat COVID-19 di Indonesia edisi 1. Bpom RI. Jakarta; 2020. 1–142 p.

Badan Pengawas Obat dan Makanan Republik Indonesia. Informatorium Obat COVID-19 di Indonesia edisi 2 November. Jakarta; 2020.

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. Journal of hepatology. 2020 Sep;73(3):566–74.

Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) IDAI (IDAI). Pedoman Tatalaksana COVID-19 Edisi 2 Agustus 2020. Jakarta; 2020. 1–101 p.

Published

2022-08-29

How to Cite

Mangiwa, J., Sumarny, R. ., Laksmitawati, D. R. ., & Septini, R. . (2022). Evaluasi Klinis dan Efek Samping Terapi Obat Antivirus Pada Pasien Covid-19 Di RSPAD Gatot Soebroto. Poltekita : Jurnal Ilmu Kesehatan, 16(2), 191–199. https://doi.org/10.33860/jik.v16i2.1333

Issue

Vol. 16 No. 2 (2022): August

Section

Original Articles
Copyright & Licensing
Copyright (c) 2022 Jeanette Mangiwa, Ros Sumarny, Dian Ratih Laksmitawati, Renni Septini

Authors who publish with Poltekita : Jurnal Ilmu Kesehatan agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 2.0 Generic License.

Poltekita : Jurnal Ilmu Kesehatan  is licensed under a Creative Commons Attribution-Share Alike 4.0 International License

You are free to:

  • Adapt, remix, transform, and build upon the material for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.